Optimization of NULOJIX (Belatacept) Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10).

Trial Profile

Optimization of NULOJIX (Belatacept) Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Belatacept (Primary) ; Alemtuzumab; Basiliximab; Mycophenolate mofetil; Prednisone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Biomarker
  • Acronyms CTOT-10; DAIT-CTOT10
  • Most Recent Events

    • 22 May 2013 Immune substudy results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 19 May 2013 Status changed from active, no longer recruiting to discontinued.
    • 19 May 2013 Results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top